

Karen Ballen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997789/publications.pdf>

Version: 2024-02-01

40
papers

1,468
citations

471371

17
h-index

414303

32
g-index

71
all docs

71
docs citations

71
times ranked

2415
citing authors

#	ARTICLE	IF	CITATIONS
1	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	2.5	35
2	Association of graft-versus-host-disease with neurologic complications: clinical paradigm and future directions. <i>Bone Marrow Transplantation</i> , 2021, 56, 1471-1473.	1.3	0
3	Exploring new therapies for children with autism: "Do no harm" does not mean do not try. <i>Stem Cells Translational Medicine</i> , 2021, 10, 823-825.	1.6	2
4	Myelofibrosis: let's go high!. <i>Bone Marrow Transplantation</i> , 2021, 56, 2864-2865.	1.3	1
5	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 837.e1-837.e10.	0.6	0
6	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
7	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	2.5	63
8	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2020, 105, 47-58.	1.7	51
9	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 882-896.	2.0	117
10	Umbilical Cord Blood Transplantation: Challenges and Future Directions. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1312-1315.	1.6	29
11	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017, 19, 272-284.	0.3	13
12	Update on umbilical cord blood transplantation. <i>F1000Research</i> , 2017, 6, 1556.	0.8	41
13	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
14	BK polyomavirus reactivation after reduced-intensity double umbilical cord blood cell transplantation. <i>Transplant Immunology</i> , 2015, 32, 116-120.	0.6	7
15	Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1883-1887.	2.0	36
16	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	1.1	22
17	Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2042-2048.	2.0	219
18	Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 730-734.	2.0	16

#	ARTICLE	IF	CITATIONS
19	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013, 122, 3074-3081.	0.6	280
20	Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1851-1858.	2.0	28
21	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011, 118, 6691-6697.	0.6	180
22	Challenges in Umbilical Cord Blood Stem Cell Banking for Stem Cell Reviews and Reports. <i>Stem Cell Reviews and Reports</i> , 2010, 6, 8-14.	5.6	64
23	New trends in transplantation: the use of Thymoglobulin [®] . <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 351-355.	1.5	6
24	Long Term Follow-up of Recipients of Combined HLA-Matched Nonmyeloablative Bone Marrow and Kidney Transplantation for Multiple Myeloma with End-Stage Renal Disease.. <i>Blood</i> , 2009, 114, 3368-3368.	0.6	1
25	Outcomes following HSCT Using Fludarabine, Busulfan, and Thymoglobulin: A Matched Comparison to Allogeneic Transplants Conditioned with Busulfan and Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 993-1003.	2.0	89
26	Comparison of Twin and Autologous Transplants for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1118-1124.	2.0	28
27	Comparable Outcomes in Nonsecretory and Secretory Multiple Myeloma after Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1134-1140.	2.0	27
28	Impaired Immune Reconstitution after Cord Blood Transplantation in Adults Is Associated with Delayed Recovery but Not Functional Impairment of CD8+T Cells.. <i>Blood</i> , 2007, 110, 1057-1057.	0.6	2
29	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007, 110, 2016-2016.	0.6	1
30	A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).. <i>Blood</i> , 2007, 110, 3126-3126.	0.6	9
31	Non-Myeloablative T-Cell Depleted (TCD) Haploidentical Hematopoietic Cell Transplantation (HCT) Followed by Donor Leukocyte Infusion(s) for Hematologic Malignancies: The MGH Experience.. <i>Blood</i> , 2007, 110, 5088-5088.	0.6	0
32	Cardiac Transplant Followed by High-Dose Melphalan and Autologous Stem Cell Transplantation (ASCT) for Patients with AL Amyloidosis and Severe Heart Failure.. <i>Blood</i> , 2007, 110, 732-732.	0.6	0
33	The Type of Upfront Induction Therapy for Newly Diagnosed Multiple Myeloma Patients Has No Significant Impact on Clinical Outcomes after Autologous Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 5128-5128.	0.6	0
34	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006, 108, 3148-3148.	0.6	1
35	Outcome of Bone Marrow Transplantation for Myelofibrosis.. <i>Blood</i> , 2005, 106, 170-170.	0.6	11
36	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. <i>Blood</i> , 2005, 106, 3027-3027.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Outcomes of Patients with Engraftment Syndrome (ES) Following Nonmyeloablative Hematopoietic Stem Cell Transplant (SCT) for Hematologic Malignancy(HM).. Blood, 2005, 106, 3661-3661.	0.6	1
38	In Vivo and Ex Vivo T-Cell Depleted (TCD) NonmyeloablativeHaploidentical Stem Cell Transplantation (NSCT) for Hematologic Malignancy (HM).. Blood, 2005, 106, 5431-5431.	0.6	0
39	Development of Late over Early Full Donor Chimerism (FDC) Results in Improved Progression-Free and Overall Survival in Patients with Advanced Malignant Lymphomas Receiving Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).. Blood, 2005, 106, 3665-3665.	0.6	0
40	Fludarabine Treatment Is Associated with Depletion of Host CD4+CD25high, FOXP3+, CTLA-4+ Cells and Increased Incidences of Full Donor Chimerism and GVHD in Non-Myeloablative Haploidentical Hematopoietic Cell Transplant Recipients.. Blood, 2005, 106, 2898-2898.	0.6	0